SYGNIS further strengthens its patent position for AX200 for the treatment of stroke

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Patents, Copyright & Trademarks

Heidelberg (euro adhoc) - SYGNIS further strengthens its patent position for
AX200 for the treatment of

Heidelberg, September 15,  2011  -  SYGNIS  Pharma  AG  (Frankfurt:  LIOK;  ISIN
DE000A1E9B74; Prime Standard), a clinical stage biotech company researching  and
developing innovative therapies for neurodegenerative diseases, today  announced
that the European Patent Office has given two notices regarding their  intention
to issue additional AX200-patents shortly. The  respective  patent  applications
cover the use of AX200 for the acute  and  chronic  stage  of  a  stroke.  These
additional patents will further strengthen SYGNIS´  patent  portfolio  of  AX200
for the treatment of stroke which consists of six patent families.

The claims of the patent application for the treatment  of  acute  stroke  cover
the actual use and dosage of AX200 as applied in the current Phase  II  efficacy
study of AX200 (AXIS 2) and as intended to be used in  clinical  practice  at  a
later stage. With a scheduled expiry date of 2028, these claims  complement  the
key patent granted in Europe in 2006 and in the USA in 2009,  covering  the  use
of AX200 for the treatment of stroke.

The claims of the second patent application  cover  the  treatment  of  patients
with AX200 in the chronic stage of a stroke. They have a scheduled  expiry  date
of  2025  and  complement  SYGNIS´  IP-position  in  the  early  recovery  phase
following a stroke.

Dr. Frank Rathgeb, CMO of SYGNIS commented: "The granting of these patents  will
considerably strengthen the protection of our approaches for  the  treatment  of
stroke with AX200 as well as  the  actual  therapeutic  regimen  for  the  acute
treatment. Especially with regard to the  top-line  data  of  the  AXIS  2-trial
which we expect to report towards the end of this calendar year,  this  improved
patent position will increase the overall value of the  AX200  project  and  the
awareness amongst potential partners."

About AX200

AX200 is a biological  molecule,  developed  by  SYGNIS  for  the  treatment  of
neurodegenerative diseases. In the indication stroke it  is  the  most  advanced
drug candidate in SYGNIS´ product pipeline. AX200 is an endogenous  protein.  As
part of the body's own protective action the  production  of  AX200  is  boosted
after brain damage. If the molecule is given as a medication  it  increases  the
existing  endogenous  response  to  the  damage.  SYGNIS  pursues   a   multiple
neurotherapeutic approach in the development  of  AX200  for  the  treatment  of
neurodegenerative diseases: AX200 stops neuronal cell death in the  acute  phase
of the disease while at the  same  time  stimulating  the  regeneration  of  the
already  damaged  CNS  through  the  stimulation  of  neurogenesis  as  well  as
arteriogenesis and the reorganisation of neuronal networks.

About SYGNIS Pharma
SYGNIS Pharma AG, headquartered in Heidelberg,  is  a  specialty  pharmaceutical
company listed in the Prime  Standard  of  the  Frankfurt  Stock  Exchange.  The
Company is focused on the research and development of innovative  therapies  for
the treatment of disorders of the Central Nervous System. SYGNIS´ core  projects
are currently Acute Stroke for which SYGNIS´ lead clinical programme  is  AX200,
as well as the preclinical KIBRA-project for the treatment  of  different  forms
of dementia. All these disorders are characterized by  the  fact  that,  as  the
disease progresses, nerve cells are damaged and die.  Although  there  is  great
medical demand, there are currently no  or  only  inadequate  treatment  options
available. Furthermore, a key element of the sustainable value creation  of  the
Company is the expansion of the product pipeline, which will be secured  through
its own developments as well as in-licensing and acquisitions.

For further information please contact:

|Dr. Franz-Werner Haas                  |
|Senior Vice President Operations       |
|+49 (0) 6221 454 812                   |
|         |

Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187

Some statements included in this  press  release,  relating  neither  to  proven
financial results nor other  historical  data,  should  be  viewed  as  forward-
looking, i.e. not definite. Such statements are  mainly  predictions  of  future
results, trends, plans or goals. These statements should not  be  considered  to
be total guarantees since given their very nature they are subject to known  and
unknown risks and imponderability and can be affected  by  other  factors  as  a
consequence of which the actual results, plans and goals  of  SYGNIS  Pharma  AG
may deviate greatly from the  established  conclusions  or  implied  predictions
contained in such statements. SYGNIS does not undertake to  publicly  update  or
revise these statements in the light of new information  or  future  results  or
for any other reason.

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6

end of announcement                               euro adhoc 

company:     SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
             Hamburg, Stuttgart, Düsseldorf, Hannover, München 
language:   English

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: